An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors

Figure 3

Forest plot of diabetes-related adverse events compared between PCSK9 inhibitors and control treatment (placebo or ezetimibe). ^a Treatment with alirocumab Q2W; ^b Treatment with alirocumab Q4W.